IQWiG comment on the current consultation version of the S3 guideline on prostate cancer published by the German Society of Urology (DGU)

In its comment, IQWiG primarily criticizes the guideline recommendations on screening for prostate cancer: Given the problems associated with PSA testing, the aim should not be to test as widely as possible and find as much as possible. In order to optimize the benefit-harm ratio, diagnostic tests should (as in Scandinavia) be focused on the basis of individual informed decisions, taking into account age, intervals and thresholds, so that clinically relevant prostate cancer can be detected.